• Bin Zhu, Xiaoguang Liu, Zhongjun Liu, Shaomin Yang, Hung-I Liao, Liang Jiang, and Feng Wei.
• Department of Orthopaedics, Peking University Third Hospital, No 49. North Garden Street, HaiDian District, Beijing 100191, People's Republic of China.
• Eur Spine J. 2012 May 1;21(5):897-904.

Background And ObjectivesTo summarise our experience treating patients with spinal malignant peripheral nerve sheath tumours (MPNSTs).MethodsWe retrospectively reviewed the records of patients diagnosed with spinal MPNSTs who received surgical treatment from January 1998 to December 2009.ResultsPostoperative follow-up data were available for 14/16 patients with spinal MPNSTs (7 men, 7 women; median age = 44 years [range: 23-68 years]). Eight of 14 (57.1%) patients had primary and 6/14 (42.9%) recurrent MPNSTs. A total of 12/14 (85.7%) patients underwent total tumour resection, whereas 2/14 (14.3%) patients underwent subtotal tumour resection. Malignancies were graded low in 4 (28.6%) and high in 10 (71.1%) cases. A total of 12/14 (85.7%) patients experienced tumour recurrence and 10/14 (71.4%) patients died during the course of follow-up. The 0.5- 1-, 3-, and 5-year survival rates were 64.3, 48.2, 32.1, and 21.4%, respectively. Overall survival was significantly associated with tumour malignant degree (P = 0.012).ConclusionDiagnosis of spinal MPNSTs should be made with reference to clinical, radiological, and pathological findings. Surgical resection is the best available option for treating spinal MPNST; however, postoperative prognosis is poor.

27 keywords...

hide…